Merck enters into a pharma licensing deal with GSK for evaluating combination therapy for renal cell carcinoma.
Merck announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.
Merck and GlaxoSmithKline entered a pharma licensing deal to study MK-3475 with pazopanib and other agents in the GlaxoSmithKline portfolio in the future.
This Phase I/II clinical trial is designed to evaluate the safety and efficacy of a combination of MK-3475 and pazopanib in treatment naïve patients with advanced renal cell carcinoma.
Further details of the collaboration were not disclosed.
View the full article at Fierce Biotech
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Merck & Co
Report: Partnering Deals and Alliances with GlaxoSmithKline
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity